VB10. NEO's joint treatment of head and neck cancer with bempeg shows great potential!

Based on very promising data observed in preclinical studies, this clinical collaboration shows that individualized cancer vaccines and T-cell proliferation stimulators can work together to induce maximum amplification of vaccine-induced T-cell cloning, providing deep and long-lasting responses and specific anti-tumor immunity.
VB10. NEO is Vaccibody's proprietary therapeutic DNA vaccine that uses cancer patients' own tumor-specific antigens (neoantigen, new antigens) to personalize treatment.
in clinical trials, VB10. NEO has been shown to induce strong neo-antigen-specific immune responses that provide clinical remission in patients with localized advanced or metastasis diseases.
bempeg is The proprietary immunostature therapy of Nektar Therapeutics, a CD122 biased IL-2 pathogenic agitant that stimulates the proliferation of these cancer-fighting immune cells by targeting CD122 specific subjects present on the surface of natural killing cells (NK cells), CD4-T cells, and CD8-T cells.
CD122, also known as the leukocyte interleukin-2 subject beta sub-base, is an important signaling subject known to increase the proliferation of these effect T-cells.
in preclinical and clinical studies, bempeg therapy causes these anti-cancer immune cells to rapidly expand and mobilize into tumor microenvironments.
VB10. NEO aims to specifically activate the immune response of the patient's immune system to tumor-specific antigens (neoantigen, new antigens), while bempeg aims to amplification and proliferation of tumor antigen-specific T cells on the periphery of the tumor and in the tumor microenvironment.
add bempeg to VB10.NEO treatments to maximize the amplification of vaccine-induced new antigen-specific T-cells for cancer treatment.
at the 2019 annual meeting of the Society for Cancer Immunotherapy (SITC), Vaccibody provided interim data on VB10.NEO treatment for a group of patients with different types of solid tumors who had received multiple cancers Treatment, and received at least one checkpoint inhibitor (CPI, Opdivo (Odivo, Navuliyu monoanti) or Keytruda (Corida, Paboliju monoanti) for 5-32 months.
, 50 percent (7/14) of patients treated with VB10.NEO received a clinical response, including four SCCHN patients.
clinical response is defined as a reduction of more than 10% in target lesions (identified at screening) or the conversion of progressive lesions into stable lesions (follow-up 37 weeks, increased lesions by 20%).
In preclinical studies, the combined application of VB10.NEO and bempeg was evaluated to demonstrate the synergy of these two mechanisms: the combined application of two therapies obtained a wider and deeper response to new antigen-specific T-cells than with each therapy alone.
In preclinical models of solid tumors, a combined application can induce strong immunogenic CD8-T cell response, and when used in association with anti-PD-1, it can induce small tumors to recede quickly, completely and permanently, and can control the disease of large tumors in the long term.
original origin: Vaccibody AS and Nektar Therapeutics Announce First Patient Dosed in a Phase 1/2a Arm Study Evaluating VB10. NEO, a Posted Neoantigen Cancer Vaccine, with Bempegaldesleukin (NKTR-214) in Patients with Squamous Cell Carcinoma of The Head and Neck.